黑龙江珍宝岛药业股份有限公司 2023 年年度股东大会 会 议 资 料 2024.05.20 1 | | 2023 年年度股东大会会议须知 | 3 | | --- | --- | --- | | | 2023 年年度股东大会会议议程 | 4 | | 议案 | 1：2023 | 年度董事会工作报告 6 | | 议案 | 2：2023 | 年度监事会工作报告 6 | | 议案 | 3：2023 | 年度财务决算报告 7 | | 议案 | 4：2024 | 年度财务预算报告 7 | | 议案 | 5：2023 | 年年度报告全文及摘要 8 | | 议案 | 6：2023 | 年度利润分配预案 9 | | 议案 | 7：关于 2024 | 年向金融机构申请授信额度及融资的议案 10 | | 议案 | 8：关于 2024 | 年为子公司提供担保额度的议案 11 | | 议案 | 9：关于续聘公司 | 2024 年度审计机构的议案 12 | | 议案 | | 10：关于董事、高级管理人员 2023 年度薪酬情况及 2024 年度薪酬方案的议案 13 | | 议案 | 11：关于监事 | 2023 年度薪酬情况及 2024 ...

证券代码：603567 证券简称：珍宝岛 黑龙江珍宝岛药业股份有限公司 投资者关系活动记录表 编号：2024-001 □特定对象调研□分析师会议□媒体采访□业绩说明会 投资者关系活 □新闻发布会□路演活动□现场参观 动类别 其他（线上电话交流会） 时 间 2024年5月5日 19:30-20:30（北京时间） 参与单位名称 中药行业证券分析师及投资机构，共计 36 家，机构名单见附 人员姓名 件。 方 式 电话会议 董事长：方同华先生 上市公司接待人 财务总监：王磊先生 员姓名 董事会秘书：张钟方女士 销售公司副总：胡彩龙先生 投资者关系活动 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-029 黑龙江珍宝岛药业股份有限公司 关于召开 2023 年度及 2024 年第一季度业绩 会议召开时间：2024 年 5 月 14 日（星期二）下午 16:00-17:00 1 说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2024 年 5 月 14 日中午 12:00 前，将关注的问题以电子邮件 的形式发送至黑龙江珍宝岛药业股份有限公司（以下简称"公司"）董事会办公 室邮箱（zbddsh@zbdzy.com），公司将结合实际情况，在信息披露允许的范围内， 就投资者普遍关注的问题在说明会上进行回复。 公司于 2024 年 4 月 30 日在上海证券交易所网站（www.sse.com.cn）披露了 《黑龙江珍宝岛药业股份有限公司 2023 年年度报告》全文及摘要与《黑龙江珍 宝岛药业股份有限公司 2024 年第一季度报告》，为便于广大投资者更全面深入 地了解公司财务状况与经营情况，公司将于 2024 年 5 月 14 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-028 黑龙江珍宝岛药业股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到国家药品监督管理 局核准签发的左乙拉西坦注射用浓溶液《药品注册证书》（证书编号：2024S00676）， 现就相关情况公告如下： 一、药品的基本情况 药品名称：左乙拉西坦注射用浓溶液 剂型：注射剂 规格：5ml：500mg 注册分类：化学药品 4 类 上市许可持有人：黑龙江珍宝岛药业股份有限公司 生产企业：黑龙江珍宝岛药业股份有限公司 药品批准文号：国药准字 H20243584 药品批准文号有效期：至 2029 年 04 月 23 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药 品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工 艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。 二、药品的其他情况 药品注册标准编号 ...

Financial Performance - The company's operating revenue for 2023 was ¥3,138,186,554.27, a decrease of 25.53% compared to ¥4,214,148,859.72 in 2022[22]. - Net profit attributable to shareholders increased by 154.93% to ¥472,740,021.12 in 2023 from ¥185,440,370.42 in 2022[22]. - The net cash flow from operating activities was -¥478,244,805.78, a decline of 46.34% compared to -¥326,792,760.53 in 2022[22]. - Basic earnings per share rose by 155.43% to ¥0.5032 in 2023 from ¥0.1970 in 2022[29]. - The weighted average return on net assets increased by 3.84 percentage points to 6.4564% in 2023 from 2.6198% in 2022[29]. - The total assets at the end of 2023 were ¥12,465,874,627.30, reflecting a 6.75% increase from ¥11,677,768,228.80 at the end of 2022[29]. - The net profit attributable to shareholders after deducting non-recurring gains and losses improved significantly, with a reduction in losses to -¥31,842,460.08 in 2023 from -¥280,408,320.73 in 2022, an improvement of 88.64%[22]. - The company achieved a comprehensive revenue growth rate of -4.0% and a profit growth rate of -16.2% during the reporting period[61]. Dividend Distribution - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares, totaling approximately 188.35 million CNY, which represents 39.84% of the net profit attributable to ordinary shareholders[5]. - The total share capital as of December 31, 2023, is 941,963,592 shares, with 941,689,128 shares eligible for the dividend distribution after accounting for treasury shares[5]. - The company has not proposed any stock dividends or capital reserve transfers in this profit distribution plan[5]. Audit and Compliance - The company has received a standard unqualified audit report from Zhongzhun Accounting Firm, ensuring the accuracy and completeness of the financial report[4]. - There are no significant risks that could materially affect the company's operations during the reporting period[7]. - The company has confirmed the absence of non-operational fund occupation by controlling shareholders and related parties[6]. - The company has not violated decision-making procedures regarding external guarantees[6]. - The company is committed to maintaining internal control and has provided detailed information in the internal control audit report[9]. Market and Product Development - The company is focusing on a strategic development plan centered around "two centers, three parks, and four platforms," aiming to enhance the entire industry chain of traditional Chinese medicine[42]. - The company emphasizes market development and customer-centric service operations to drive product volume and improve market access[43]. - The company is committed to strict GMP production management, optimizing production capacity and product structure, and enhancing production cost control[44]. - The company is actively participating in the national centralized procurement policy, which aims to expand the range of drugs included in procurement[64]. - The company is expanding its product line through mergers and acquisitions and innovation in research and development[66]. - The company is pursuing new product launches and expanding into new channels and terminals to foster business growth[74]. Research and Development - The company has 4 innovative drug projects and 39 generic drug projects under development, with a positive trend of new product applications and approvals each year[121]. - The innovative drug ZBD1006, a second-generation FGFR inhibitor, is currently in the Phase I clinical trial stage and is expected to treat multiple types of cancer[121]. - The company is focusing on five major R&D areas, including traditional Chinese medicine and chemical drug mergers, to enhance product clusters in cardiovascular, respiratory, and immune systems[188]. - The company has established a comprehensive R&D incubation park covering traditional Chinese medicine, chemical drugs, and biological drugs to support the pharmaceutical industry's technical needs[193]. Sales and Marketing - The company has developed a comprehensive marketing network covering the entire country, aiming to enhance sales and service efficiency[74]. - The company maintains a diverse marketing strategy, utilizing a combination of different product types and channels to enhance brand value and economic returns, supported by a strong marketing service team and extensive distribution network[104]. - The company emphasizes precise market positioning and segmentation, continuously optimizing marketing strategies to expand product coverage and drive sales growth[106]. - The company is committed to enhancing brand influence through academic promotion and marketing activities, establishing a unified operational standard for brand academic services to increase brand visibility[107]. Financial Position and Cash Flow - The net cash flow from financing activities was 765,692,370.02 CNY, an increase of 282.77% year-on-year[160]. - Cash and cash equivalents at the end of the period amounted to 1,454,040,157.07 CNY, representing 11.66% of total assets, up 45.20% from the previous period[163]. - The company's long-term borrowings increased to 1,298,000,000.00 CNY, a rise of 182.17% compared to the previous period[163]. Industry Trends - The pharmaceutical industry in 2023 saw a revenue decline of 4% and a profit decrease of 16.2%, while traditional Chinese medicine sectors experienced positive growth[53]. - National health expenditure reached 8.5327 trillion yuan in 2022, with a per capita expenditure of 6,044 yuan, reflecting an 11% year-on-year increase[55]. - The total number of medical visits in 2023 was 9.56 billion, representing a 13.5% increase compared to 2022[55]. - The government continues to release supportive policies for the development of traditional Chinese medicine, indicating a strong commitment to the industry's growth[56].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,117,297,002.98, representing a decrease of 27.09% compared to the same period last year[4] - Net profit attributable to shareholders of the listed company was CNY 293,365,824.90, an increase of 15.43% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 281,649,753.39, up 18.23% from the previous year[4] - Basic earnings per share were CNY 0.3123, an increase of 15.75% year-on-year[4] - Diluted earnings per share were CNY 0.3118, also up 15.55% compared to the same period last year[4] - The weighted average return on equity was 3.81%, an increase of 0.29 percentage points year-on-year[4] - The net profit for the current period is 293,272,864.09, an increase from 254,567,799.24 in the previous period, representing a growth of approximately 15.2%[50] - The total profit for the current period is 364,262,078.51, compared to 299,979,137.44 in the previous period, indicating an increase of about 21.4%[50] - The basic earnings per share (EPS) for the current period is 0.3123, up from 0.2698 in the previous period, reflecting a growth of approximately 15.7%[51] - The diluted EPS for the current period is 0.3118, also an increase from 0.2698 in the previous period, showing a growth of around 15.6%[51] Cash Flow - The net cash flow from operating activities was negative at CNY -103,296,907.81, reflecting an increase in outflow of 32.61% compared to last year[4] - In Q1 2024, the cash inflow from operating activities was CNY 451,288,232.60, a decrease of 64.0% compared to CNY 1,254,861,762.57 in Q1 2023[31] - The cash outflow from operating activities totaled CNY 554,585,140.41, down 60.7% from CNY 1,408,139,619.12 in the previous year[32] - The net cash flow from operating activities was negative at CNY -103,296,907.81, an improvement from CNY -153,277,856.55 in Q1 2023[32] - Cash inflow from financing activities was CNY 551,893,257.89, down 54.2% from CNY 1,205,000,000.00 in the previous year[32] - The company received CNY 550,000,000.00 in borrowings, a decrease from CNY 1,205,000,000.00 in Q1 2023[32] - The net cash flow from financing activities is 63,436,562.37, a significant improvement compared to -23,036,839.47 in the previous period[55] - The ending cash and cash equivalents balance is 1,365,772,528.81, up from 824,842,855.30 in the previous period, indicating a growth of approximately 65.5%[55] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 12,880,364,470.24, a 3.32% increase from the end of the previous year[15] - Current assets totaled CNY 7,626,089,907.84, an increase of 6.4% from CNY 7,167,666,681.72 in the previous year[45] - Total liabilities amounted to CNY 4,546,366,012.75, an increase of 2.7% from CNY 4,425,219,914.44 in the previous year[45] - Total assets reached CNY 12,880,364,470.24, up from CNY 12,465,874,627.30, reflecting a growth of 3.3%[46] - Long-term investments increased to CNY 701,280,660.73, up from CNY 673,412,423.69, representing a growth of 4.0%[45] Expenses - Operating costs for Q1 2024 were CNY 680,916,308.96, down 44.4% from CNY 1,225,023,970.30 in Q1 2023[48] - Research and development expenses for Q1 2024 were CNY 3,957,691.13, a decrease of 71.8% compared to CNY 14,040,635.04 in Q1 2023[48] - The company reported a decrease in sales expenses to CNY 99,640,998.01, down 60.2% from CNY 250,719,922.47 in Q1 2023[48] Shareholder Information - The total number of common shareholders at the end of the reporting period was 24,767[38] - The largest shareholder, Heilongjiang Chuangda Group Co., Ltd., holds 50.00% of the shares[38] Other Income - The company reported non-operating income of CNY 13,018,283.66 from government subsidies related to normal business operations[35] - The company reported a fair value change gain of 71,171.66, contrasting with a loss of -25,254.46 in the previous period[50] - The company experienced credit impairment losses of -59,080,434.20, which is a decrease from -30,166,769.26 in the previous period, indicating an improvement in credit quality[50]

黑龙江珍宝岛药业股份有限公司（以下简称“珍宝岛药业”）是一家注重产品创新的制药企业，上世纪90 年代创立之初的几年里成功研发并上市多个用于治疗心脑血管疾病的高端中药产品，为企业后来在市场 上打响品牌奠定了坚实的基础。 “珍宝岛药业在近30年的发展历程中，一直在深耕药品创新研发，我们坚持‘中药为主、中西并重’的药 品研发战略布局，现已建立‘一心四院’的药品研发体系，涵盖中药、化药、生物药产品的创新研 发。”珍宝岛药业总经理闫久江说。 珍宝岛药业坚持“两创两新”发展战略，一方面十分注重创新产品的研发，另一方面坚持推动生产制造朝 着智能型、智慧化方向发展。 在药品研发方面，珍宝岛建立了“一心四院”的药品研发体系，以北京科研管理中心为管理中枢与纽带， 协同哈尔滨、北京、上海、杭州四个药物研究院开展中药、化药、生物药的研发。当前，公司在研中药 1.1类创新药，目前已完成药学、毒理研究及药效学研究，并与CDE申请了沟通交流会，正在开展新药 临床试验申请。用于风湿的古代经典名方项目，目前已经完成药学研究，正在与CDE进行沟通交流。 公司持续关注行业合作及优质资源的整合，加速开展中药并购工作，利用营销预测和市场规模建立模 型 ...

北京市兰台律师事务所 关于 黑龙江珍宝岛药业股份有限公司 回购注销部分激励对象已获授但尚未解除限售的限制性 股票的 法律意见书 北京市兰台律师事务所(以下简称"兰台"或"本所")接受黑龙江珍宝岛 药业股份有限公司(以下简称"公司"或"珍宝岛")的委托,作为公司 2023 年限制性股票激励计划(以下简称"本次股权激励计划")的特聘专项法律顾问。 本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》(以下简称"《证券法》")、中国证券监督管理委员会 (以下简称"中国证监会")《上市公司股权激励管理办法》(以下简称"《管 理办法》")及其他有关法律、法规和规范性文件,及《黑龙江珍宝岛药业股份 有限公司 2023年限制性股票激励计划(草案)》〈以下简称"《激励计划(草 案）》"）就公司本次回购注销部分激励对象已获授但尚未解除限售的限制性股 票(以下简称"本次回购注销")涉及的相关法律事宜出具本法律意见书。 地址:北京市朝阳区曙光西里甲1号第三置业B座29层 电话: （8610）52287799 传真: （8610）58220039 邮编: 100028 网址: www.lanta ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-016 黑龙江珍宝岛药业股份有限公司 关于回购注销部分限制性股票通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、通知债权人的原由 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）于 2024 年 4 月 3 日 召开第五届董事会第八次会议和第五届监事会第七次会议，审议通过了《黑龙江 珍宝岛药业股份有限公司关于公司回购注销部分激励对象已获授但尚未解除限 售的限制性股票的议案》。鉴于公司 2023 年限制性股票激励计划授予的 2 名激 励对象已离职，根据《上市公司股权激励管理办法》及《黑龙江珍宝岛药业股份 有限公司 2023 年限制性股票激励计划（草案）》的有关规定，公司董事会决定 对其已获授但尚未解除限售的 137,232 股限制性股票进行回购注销，回购价格为 8.432 元/股。本次回购注销完成后，公司总股本将由 941,963,592 股减少至 941,826,360 股，注册资本由人民币 941,963,592 元减少至人民币 9 ...

监事会认为：公司本激励计划授予的 2 名激励对象已离职，根据《上市公司 股权激励管理办法》及《黑龙江珍宝岛药业股份有限公司 2023 年限制性股票激 励计划（草案）》的有关规定，上述激励对象已获授但尚未解除限售的 137,232 股限制性股票应当由公司回购注销。 公司本次回购注销部分激励对象已获授但尚未解除限售的限制性股票符合 公司《黑龙江珍宝岛药业股份有限公司 2023 年限制性股票激励计划（草案）》及 相关法律法规的规定，程序合法合规，不会对公司的财务状况和经营成果产生重 大影响，也不会损害公司及全体股东利益。因此，监事会同意公司本次回购注销 部分激励对象已获授但尚未解除限售的限制性股票。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案尚需提交公司股东大会审议。 具体内容详见同日在上海证券交易所网站（www.sse.com.cn）披露的《黑龙 江珍宝岛药业股份有限公司关于公司回购注销部分激励对象已获授但尚未解除 限售的限制性股票的公告》（公告编号：临 2024-015）。 证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-014 黑龙江珍宝岛药业股份有限公司 第五届监事会第七 ...